JMP Securities analyst Jason Butler said he is confident that the results from Acadia's Phase 3 Harmony study will support label expansion, noting that there are about 1.2M Dementia-Related Psychosis diagnosed patients in the U.S., which is up to 10 times larger than the PDP indication already approved for Nuplazid. The analyst, who also sees the trial success highlighting further opportunities for label expansion into MDD and schizophrenia negative symptoms, keeps an Outperform rating on Acadia shares and raised his price target on the stock to $55 from $30.